NYSE · ADCT
ADC Therapeutics SA
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ADCT: Nov 9, 2026
ADC Therapeutics SA Common Shares is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.21. The reported EPS for the same quarter last year was $-0.3.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Dec 2026 | $-0.23 | $-0.23 | $-0.23 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · The Motley Fool · MarketBeat- RTTNews · Oct 29, 2:12 PM EDTADC Therapeutics Announces Japan Filing For ZYNLONTA In Relapsed Or Refractory Lymphoma(RTTNews) – ADC Therapeutics SA (ADCT) announced that its Japanese licensing partner, Tanabe Pharma Corporation, filed a marketing authorization application with Japan's Ministry of Health, Labour and Welfare for ZYNLONTA (loncastuximab tesirine-lpyl) to treat patients with relap
- Zacks · Oct 28, 6:30 PM EDTNeoGenomics (NEO) Q3 Earnings and Revenues Beat EstimatesNeoGenomics (NEO) delivered earnings and revenue surprises of +16.67% and +0.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Oct 8, 12:44 PM EDTADC Therapeutics Announces $86.6M Financing And Debt Restructuring; Stock Up(RTTNews) – ADC Therapeutics (ADCT) announced a comprehensive financial restructuring, including an $86.6 million private placement, amendments to its HealthCare Royalty agreement and refinancing of its senior secured loan, aimed at strengthening its balance sheet and extending i
- The Motley Fool · Aug 20, 3:49 PM EDTADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 13, 4:04 PM EDTADC Therapeutics Q2 Earnings Call HighlightsADC Therapeutics (NYSE:ADCT) reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment’s commercial performance remained broadly consistent with recent quarters. The company
- Zacks · Aug 13, 8:50 AM EDTADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue EstimatesADC Therapeutics (ADCT) delivered earnings and revenue surprises of +42.11% and -4.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 6, 9:50 AM EDTIovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue EstimatesIovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +35.29% and +13.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 28, 8:15 AM EDTAlkermes (ALKS) Reports Break-Even Earnings for Q2Alkermes (ALKS) delivered earnings and revenue surprises of +100.00% and +9.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 26, 10:33 AM EDTWeekly Buzz: IONS, MRK Get FDA Approvals; ACHV Gets CRL; ADCT Cuts Jobs; TECH Acquired(RTTNews) – This week, the biotech sector delivered a mix of FDA and EU approvals, strategic reorganizations, layoff, acquisitions, and late-stage clinical readouts across oncology, metabolic disease, neurology and immunology.
- RTTNews · Jun 25, 2:15 AM EDTADC Therapeutics Cuts Workforce To Advance ZYNLONTA Portfolio In B-Cell Lymphoma(RTTNews) – ADC Therapeutics SA (ADCT), a commercial-stage biotechnology company, announced it has initiated a strategic reorganisation, including a workforce reduction, to focus resources on key initiatives to advance the ZYNLONTA franchise.
- RTTNews · Jun 23, 6:03 AM EDTTango Appoints Robert Azelby To Board Of Directors(RTTNews) – Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors.
- Zacks · Jun 4, 10:43 AM EDTADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma DataADC Therapeutics stock plunges 53% after-hours as investors focus on safety concerns in a phase III DLBCL study of Zynlonta, despite meeting its primary efficacy goal.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for ADC Therapeutics SA from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.